A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Slides:



Advertisements
Similar presentations
Clinical Outcomes with Newer Antihyperglycemic Agents
Advertisements

Clinical Outcomes with Newer Antihyperglycemic Agents
Cardiovascular Challenges in Diabetes
Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?
Updates on CVOT Data and Clinical Comparisons That Matter
Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
CV Risk Management in T2DM: What Did We Learn From EASD 2016?
Select Topics in Cardiovascular Medicine
Managing Complex Hypertension: What Every Physician Should Know
Updates on Outcomes for Novel T2D Therapies
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.
Early Type 2 Diabetes Mellitus: A Cardiovascular Disease
Emerging CVOT Data and Clinical Application
Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.
Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.
Impacting CV Risk With Diabetes Medications
EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.
Impacting CV Risk With Diabetes Medications
Clinical Application of New CV Outcomes Data
T2DM and CV Outcomes Trials: A Deep Dive!
A Deep Dive Into CVOTs.
Diabetes Increases Risk of CVD
Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.
ADA/EASD Position Statement: Approach to Hyperglycemia Management
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.
Growing Diabetes Pandemic Worldwide
Tackling CV Risk in T2DM.
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Breaking Down the CVOTs
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
Type 2 Diabetes Management:  Where Are We Heading in Our Efforts to Control CV Risk?
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
Learning Objectives Metabolic Abnormalities Associated With T2D.
Antihyperglycemic Therapy
CV Outcomes and Adherence With GLP-1 RAs
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
The Role of the Kidney in Glucose Control
Updates From ACC.
Add-On Therapy to Insulin in T1DM Management
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Elevated Admission Plasma Glucose Following ACS
Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Improving Overall Health
DECLARE-TIMI 58.
2015 EASD In Review: CV Risk management in t2dm
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
What's New in Oral Combination Therapy for Type 2 Diabetes?
Emerging Advances in Reducing Renal Complications of T2D
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?
In the Know.
Presentation transcript:

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities

Introduction/Overview

T2DM as a Risk Factor for CVD

Mortality and CVD in T2DM: Data From the Swedish Registry Study

Close Linkage Between T2DM and HF

T2DM and Patients at CV Risk: Many Targets but Questionable Success

A Correlation Exists Between HF and T2DM

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

SAVOR-TIMI, EXAMINE, TECOS: Topline Results

EMPA-REG: Primary Outcome (3-point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-REG: Results for CV Death

Key Outcome of EMPA-REG (but not to be Found in the Published Papers)

Potential Mechanisms for CV Benefit Associated With Empagliflozin

HF Improvement: Differential Volume Regulation by SGLT2 Inhibitors vs Loop Diuretics

The "Fuel Hypothesis" as Explanation of Empagliflozin's Cardiorenal Benefits

Glucose and Body Weight Reduction Associated With SGLT2 Inhibitors

The Importance of Addressing CVD in the Context of T2DM

Kidney Damage and SGLT2 Inhibitors

GLP-1 RAs and SGLT2 Inhibitors: Anti-Glycemic Agents or CV Drugs?

ELIXA: Primary Outcome: CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for Unstable Angina

LEADER: Primary Outcome*

LEADER: CV Death

SUSTAIN-6 (Semaglutide): Primary Outcome Results

LEADER Subgroup Analysis: Effect of Liraglutide on Patients With T2DM and Polyvascular Disease

Benefit of Empagliflozin in Patients With HF?

Clear-Cut Clinical Roles for Empagliflozin and Liraglutide Based on Different MOAs

New Paradigm for Treating the Patient With Both T2DM and CVD

Hypothetical Trial: Combination of GLP-1 RA and SGLT2 Inhibitor With CV Endpoints

Linkage Between Elevated Glucose and CVD/Events: Correlation or Causality?

Pharmacologic Therapy for T2DM: ADA 2018 Recommendations (4)

Summary and Conclusions

Abbreviations

Abbreviations (cont)